Clinical trial
Asian Botulinum Clinical Trial Designed for Early Stroke Spasticity
NCT00234546 · Ipsen, Industry · Completed
Key facts
| NCT number | NCT00234546 |
|---|---|
| Title | Asian Botulinum Clinical Trial Designed for Early Stroke Spasticity |
| Official title | A 24-week Prospective, Multicentre, Randomised, Double-blind, Placebo Controlled Study of Dysport® Injection for the Treatment of Upper Limb Spasticity in Early Stroke. |
| Lead sponsor | Ipsen, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Muscle Spasticity, Cerebrovascular Accident |
| Intervention type | Biological, Drug |
| Interventions | Botulinum toxin type A, Placebo |
| Enrollment | 162 |
| Start date | Feb 1, 2003 |
| Completion | Oct 1, 2007 |
| First posted | Oct 7, 2005 |
| Last update posted | Jul 26, 2019 |
| Countries | Hong Kong, Malaysia, Philippines, Singapore, Thailand |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: